Welcome to our dedicated page for Nutriband Warrant news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband Warrant stock.
Nutriband Inc. is a health and pharmaceutical company based in Oviedo, Florida, primarily focusing on transdermal and topical technologies for product development. Their lead product, AVERSA technology, works to prevent drug abuse and diversion, especially opioids. Most revenue is generated from consumer transdermal and coated products. Nutriband is progressing towards a 505(b)(2) NDA submission to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025.
The recent private placement of $8.4 million will fund the commercial development of AVERSA Fentanyl for NDA filing. Nutriband is working on the commercial scale-up and pivotal clinical study for FDA approval. AVERSA technology aims to revolutionize opioid patches with abuse-deterrent properties, making them safer and more effective.
By utilizing their proprietary AVERSA™ abuse-deterrent technology, Nutriband is dedicated to preventing drug abuse and misuse while ensuring accessibility to those in need. With a focused approach on innovation and safety, Nutriband is positioned to make a significant impact in the pharmaceutical industry.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced it has completed the necessary steps to submit its application to Ecuador's Health Register, allowing for the distribution of medical devices and cosmetic products in South America. This move opens access to the Andean Community, which includes four countries: Colombia, Ecuador, Peru, and Bolivia, with a combined population exceeding 114 million. Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse-deterrent fentanyl patch utilizing AVERSA™ technology. The company is navigating various risks associated with product development and regulatory approvals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will present at the RHK Capital Disruptive Growth Conference on December 5, 2022, at 10:20 AM in New York City. The presentation will focus on the company's AVERSA technology and its market potential. The conference will host executives from up to 30 growth-oriented companies, engaging with institutional investors and financial advisors. Nutriband specializes in transdermal pharmaceutical products, with a lead product under development being an abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NTRB, NTRBW) announced the granting of Canadian patent No. 2,937,649 for its AVERSA™ transdermal abuse deterrent technology. The patent issued on November 1, 2022, enhances protection for the AVERSA™ products across North America, following similar patents granted in the U.S. and Mexico. This technology aims to mitigate opioid abuse, particularly in light of Canada's opioid crisis. Nutriband's AVERSA™ Fentanyl system is projected to achieve peak U.S. sales between $80M and $200M, addressing a significant public health issue while ensuring patient access.
FAQ
What is the current stock price of Nutriband Warrant (NTRBW)?
What is Nutriband Inc.'s primary focus?
What is AVERSA technology?
What is the recent achievement of Nutriband Inc.?
What is Nutriband Inc.'s goal in the pharmaceutical industry?
How is Nutriband Inc. striving for innovation?
